Takeda to sell nearly new Shire plant with 200 employees

Takeda, which has been cutting costs after closing its $60 billion deal for Shire last year, is putting a Shire plant up for sale. (Takeda)

Shire had big ambitions when it built a $400 million biologics plant in Ireland it said would help achieve its “ambition of becoming the world’s leading biotechnology company.” Well, Shire no longer exists. It was absorbed into Japan’s Takeda, which now intends to sell the plant with 200 employees. 

The company said in an emailed statement that a review of manufacturing facilities after its $60 billion buyout of Shire found it had excess capacity, so it decided to “divest its biologics facility in Dunboyne.” It said it intends to sell the nearly-new plant as a going concern and does not intend any layoffs. 

RELATED: Takeda whittles away costs—and assets—to keep its debt-cutting promises

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Takeda said it is shopping the facility around and, given the capabilities of the plant and its workforce, is confident it will be “an attractive asset” to a buyer. 

"Day-to-day operations at the facility will continue at pace as Takeda continues to commission and validate the facility, ready the site for a buyer and prepare the team for the future delivery of products for patients," Takeda's statement says.

The company pointed out it will keep other facilities in Ireland, including its site in Grange Castle near Dublin. 

It last year opened a $42.8 million plant at the Grange Castle site to produce its oral multiple myeloma drug Ninlaro. Takeda also is investing about $30.5 million on a standalone modular cell therapy facility and adding about 70 jobs at the site for the production of a novel stem cell therapy.

Suggested Articles

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.

BioCryst has scored FDA approval for Orladeyo, the first oral option to prevent hereditary angioedema attacks in patients 12 and older.